1、(崀搀栀！愨崀崀崀讀缁缀栂堀悾樁螏頀h椀漂錃錃錃崌焌礌礌礌匌漀昀漀猀戀甀瘀椀爀椀洀瀀甀爀椀琀礀愀琀愀匀栀攀攀琀攀搀栀攀洀砀瀀爀攀猀猀瀀搀昀瀀椀挀最椀昀匀漀昀漀猀戀甀瘀椀爀椀洀瀀甀爀椀琀礀愀琀愀匀栀攀攀琀攀搀栀攀洀砀瀀爀攀猀猀瀀搀昀尀尀搀攀攀戀愀戀戀愀搀愀攀戀爀愀氀匀夀猀爀愀琀爀甀刀儀栀爀昀漀圀稀稀氀漀娀栀眀匀漀昀漀猀戀甀瘀椀爀椀洀瀀甀爀椀琀礀愀琀愀匀栀攀攀琀攀搀栀攀洀砀瀀爀攀猀猀昀攀戀愀搀攀挀愀搀愀搀搀搀挀匀漀昀漀猀戀甀瘀椀爀椀洀瀀甀爀椀琀礀愀琀一漀夀漀氀攀挀甀氀愀爀漀爀洀甀氀愀舀舠舀褠一茀传褀倠漀氀攀挀甀氀愀爀圀攀椀最栀琀吀愀爀最攀琀嘀倀愀琀栀眀愀礀渀琀椀椀渀昀攀挀琀椀漀渀匀琀漀爀愀最攀倀氀
2、攀愀猀攀猀琀漀爀攀琀栀攀瀀爀漀搀甀挀琀甀渀搀攀爀琀栀攀爀攀挀漀洀洀攀渀搀攀搀挀漀渀搀椀琀椀漀渀猀椀渀琀栀攀伀匀漀氀瘀攀渀琀愀洀瀀匀漀氀甀戀椀氀椀琀礀渀嘀椀琀爀漀洀椀渀匀伀漀渀挀攀渀琀爀愀琀椀漀渀匀漀氀瘀攀渀琀愀猀猀洀最洀最洀最洀洀洀洀洀洀洀洀倀爀攀瀀愀爀椀渀最匀琀漀挀欀匀漀氀甀琀椀漀渀猀洀洀洀洀倀氀攀愀猀攀爀攀昀攀爀琀漀琀栀攀猀漀氀甀戀椀氀椀琀礀椀渀昀漀爀洀愀琀椀漀渀琀漀猀攀氀攀挀琀琀栀攀愀瀀瀀爀漀瀀爀椀愀琀攀猀漀氀瘀攀渀琀伀伀吀嘀吀夀攀猀挀爀椀瀀琀椀漀渀匀漀昀漀猀戀甀瘀椀爀椀洀瀀甀爀椀琀礀椀猀琀栀攀氀攀猀猀愀挀琀椀瘀攀椀洀瀀甀爀椀琀礀漀昀匀漀昀漀猀戀甀瘀椀爀匀漀昀漀猀戀甀瘀椀爀椀猀愀渀愀挀琀
3、椀瘀攀椀渀栀椀戀椀琀漀爀漀昀嘀刀一爀攀瀀氀椀挀愀琀椀漀渀椀渀琀栀攀嘀爀攀瀀氀椀挀漀渀愀猀猀愀礀搀攀洀漀渀猀琀爀愀琀攀猀瀀漀琀攀渀琀愀渀琀椀栀攀瀀愀琀椀琀椀猀瘀椀爀甀猀嘀愀挀琀椀瘀椀琀礀愀甀琀椀漀渀倀爀漀搀甀挀琀栀愀猀渀漀琀戀攀攀渀昀甀氀氀礀瘀愀氀椀搀愀琀攀搀昀漀爀洀攀搀椀挀愀氀愀瀀瀀氀椀挀愀琀椀漀渀猀漀爀爀攀猀攀愀爀挀栀甀猀攀漀渀氀礀吀攀氀愀砀洀愀椀氀琀攀挀栀攀搀栀攀洀砀瀀爀攀猀猀挀漀洀搀搀爀攀猀猀攀攀爀倀愀爀欀爀匀甀椀琀攀儀漀渀洀漀甀琀栀甀渀挀琀椀漀渀一唀匀倀爀漀搀甀挀琀愀琀愀匀栀攀攀琀渀栀椀戀椀琀漀爀猀最漀渀椀猀琀猀匠挀爀攀攀渀椀渀最椀戀爀愀爀椀攀猀眀眀眀攀搀栀攀洀砀瀀爀攀猀猀挀漀洀攀搀栀
4、攀洀砀瀀爀攀猀猀靓匀！言茀渀7堀崀牯:h“胔-輀2棙什i缀$Sofosbuvir-impurity-F-DataSheet-MedChemExpress.pdfpic1.gifSofosbuvirimpurityFDataSheetMedChemExpress.pdf2019-5305ab1dd60-a7c9-440c-a1da-2ab532cdc868Pt7dkMjmY7H4aNVG/1ennO7ySp+pYAslqJC40560cQg8nvWHg4AB5w=Sofosbuvir,impurity,DataSheet,MedChemExpressdde2507198ccfc2bc232de0
5、7fa2382e5Sofosbuvir impurity FCat. No.: HY-I0406CAS No.: 1337482-17-3Molecular Formula: CHFNOPMolecular Weight: 798.69Target: HCVPathway: Anti-infectionStorage: Please store the product under the recommended conditions in the COA.Solvent & SolubilityIn Vitro 10 mM in DMSOConcentrationSolvent Mass 1
6、mg 5 mg 10 mg1 mM 1.2521 mL 6.2603 mL 12.5205 mL5 mM 0.2504 mL 1.2521 mL 2.5041 mLPreparing Stock Solutions10 mM 0.1252 mL 0.6260 mL 1.2521 mLPlease refer to the solubility information to select the appropriate solvent.BIOLOGICAL ACTIVITYDescription Sofosbuvir impurity F, an diastereoisomer of sofos
7、buvir, is the impurity of sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.IC & Target HCV1Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-
8、mail: techMedChemEAddress: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USAProduct Data Sheet InhibitorsAgonistsScreening Librarieswww.MedChemE1MedChemExpress0001500006先进医疗20190530092802878948S!貜!貿賿鳺鬐鳋谐鸐褐1!預鰀1輐1!跊鸐趮鶈鷉鼀刡鈐脀瀀怐酰鄀恰瀐灰怀恠酠一舐脀鄀脀鈀瀀灰瀀Z娀(退崀搀栀崀堂崀退崀讀缁缀惃樁螏頀h椀漂錃錃錃鄃鄌鄌匌漀昀漀猀戀甀瘀椀爀椀洀瀀甀爀椀琀礀愀琀愀匀栀
9、攀攀琀攀搀栀攀洀砀瀀爀攀猀猀瀀搀昀瀀椀挀最椀昀匀漀昀漀猀戀甀瘀椀爀椀洀瀀甀爀椀琀礀愀琀愀匀栀攀攀琀攀搀栀攀洀砀瀀爀攀猀猀瀀搀昀尀尀戀戀搀挀挀戀戀戀攀挀昀愀昀匀唀洀夀瘀稀吀圀搀吀唀伀伀刀吀漀夀琀欀唀稀一夀攀礀圀爀稀焀椀挀吀攀攀夀眀匀漀昀漀猀戀甀瘀椀爀椀洀瀀甀爀椀琀礀愀琀愀匀栀攀攀琀攀搀栀攀洀砀瀀爀攀猀猀愀昀愀戀攀愀搀挀昀戀昀挀攀昀匀漀昀漀猀戀甀瘀椀爀椀洀瀀甀爀椀琀礀愀琀一漀夀匀一漀漀氀攀挀甀氀愀爀漀爀洀甀氀愀舀舠舀褠一茀传褀倠漀氀攀挀甀氀愀爀圀攀椀最栀琀吀愀爀最攀琀嘀倀愀琀栀眀愀礀渀琀椀椀渀昀攀挀琀椀漀渀匀琀漀爀愀最攀倀氀攀愀猀攀猀琀漀爀攀琀栀攀瀀爀漀搀甀挀琀甀渀搀攀爀琀栀攀爀攀挀漀洀洀攀渀搀攀
10、搀挀漀渀搀椀琀椀漀渀猀椀渀琀栀攀伀匀漀氀瘀攀渀琀愀洀瀀匀漀氀甀戀椀氀椀琀礀渀嘀椀琀爀漀洀椀渀匀伀漀渀挀攀渀琀爀愀琀椀漀渀匀漀氀瘀攀渀琀愀猀猀洀最洀最洀最洀洀洀洀洀洀洀洀倀爀攀瀀愀爀椀渀最匀琀漀挀欀匀漀氀甀琀椀漀渀猀洀洀洀洀倀氀攀愀猀攀爀攀昀攀爀琀漀琀栀攀猀漀氀甀戀椀氀椀琀礀椀渀昀漀爀洀愀琀椀漀渀琀漀猀攀氀攀挀琀琀栀攀愀瀀瀀爀漀瀀爀椀愀琀攀猀漀氀瘀攀渀琀伀伀吀嘀吀夀攀猀挀爀椀瀀琀椀漀渀匀漀昀漀猀戀甀瘀椀爀椀洀瀀甀爀椀琀礀愀渀搀椀愀猀琀攀爀攀漀椀猀漀洀攀爀漀昀猀漀昀漀猀戀甀瘀椀爀椀猀琀栀攀椀洀瀀甀爀椀琀礀漀昀猀漀昀漀猀戀甀瘀椀爀匀漀昀漀猀戀甀瘀椀爀倀匀椀猀愀渀椀渀栀椀戀椀琀漀爀漀昀嘀刀一爀攀瀀氀椀
11、挀愀琀椀漀渀搀攀洀漀渀猀琀爀愀琀攀猀瀀漀琀攀渀琀愀渀琀椀栀攀瀀愀琀椀琀椀猀瘀椀爀甀猀愀挀琀椀瘀椀琀礀蔀耠愀洀瀀吀愀爀最攀琀嘀嬀崀愀甀琀椀漀渀倀爀漀搀甀挀琀栀愀猀渀漀琀戀攀攀渀昀甀氀氀礀瘀愀氀椀搀愀琀攀搀昀漀爀洀攀搀椀挀愀氀愀瀀瀀氀椀挀愀琀椀漀渀猀漀爀爀攀猀攀愀爀挀栀甀猀攀漀渀氀礀吀攀氀愀砀洀愀椀氀琀攀挀栀攀搀栀攀洀砀瀀爀攀猀猀挀漀洀搀搀爀攀猀猀攀攀爀倀愀爀欀爀匀甀椀琀攀儀漀渀洀漀甀琀栀甀渀挀琀椀漀渀一唀匀倀爀漀搀甀挀琀愀琀愀匀栀攀攀琀渀栀椀戀椀琀漀爀猀最漀渀椀猀琀猀匠挀爀攀攀渀椀渀最椀戀爀愀爀椀攀猀眀眀眀攀搀栀攀洀砀瀀爀攀猀猀挀漀洀攀搀栀攀洀砀瀀爀攀猀猀靓匀言茀渀7萀崀梙:h胔-h輀2棙什i缀
12、$Sofosbuvir-impurity-L-DataSheet-MedChemExpress.pdfpic1.gifSofosbuvirimpurityLDataSheetMedChemExpress.pdf2019-530d5fcdc33-3371-4455-81f4-d2fc64ed668cVHdTNSbaLPU53YES3bInkjhJPYkkMbpYcrf8XhDVVnZXzLR6Lxar+g=Sofosbuvir,impurity,DataSheet,MedChemExpressb65ec56e86c95c45b43d5c62554d04b5Sofosbuvir impurity
13、LCat. No.: HY-I1196Molecular Formula: CHFNOPMolecular Weight: 545.45Target: HCVPathway: Anti-infectionStorage: Please store the product under the recommended conditions in the COA.Solvent & SolubilityIn Vitro 10 mM in DMSOConcentrationSolvent Mass 1 mg 5 mg 10 mg1 mM 1.8333 mL 9.1667 mL 18.3335 mL5
14、mM 0.3667 mL 1.8333 mL 3.6667 mLPreparing Stock Solutions10 mM 0.1833 mL 0.9167 mL 1.8333 mLPlease refer to the solubility information to select the appropriate solvent.BIOLOGICAL ACTIVITYDescription Sofosbuvir impurity L, an diastereoisomer of sofosbuvir, is the impurity of sofosbuvir. Sofosbuvir (
15、PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.IC & Target HCV1Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: techMedChemEAddress: 1 Deer Park Dr, Suite Q
16、, Monmouth Junction, NJ 08852, USAProduct Data Sheet InhibitorsAgonistsScreening Librarieswww.MedChemE1MedChemExpress0001500006先进医疗20190530092804190923S蠐訐贐!1!舁腐怀鈀脐瀀灀瀐灰偰酐酠脀怀恰酠鄀鄀脀灰灐腰鄀鄀瀀酠恠腠怀恰灰艠怐偰偰灀酠腀怐恠怐倀腰舠怠怐怀堀老呻鎇芽胊賉!貜!貿賿鳺鬐鳋谐鸐褐!預鰀1輐!跊鸐趮鶈鷉鼀刡瀀偠恠恐偠倐恠脀瀀偠酐鄀灰腠脀瀀脐脀鄀瀀偐脀瀀偠酠舐怀怀瀀刀鸀尀86db-44af-8e44-4414d07007e1BN73y
17、SvHRRqTFXRZ7TgUo3a4dFonPV+ZJgNc+wPgR5ZgEBFfiGw1EA=Dimesna,DataSheet,MedChemExpressb03fff3455295b6040c283b05b1caa11DimesnaCat. No.: HY-B1022CAS No.: 16208-51-8Molecular Formula: CHNaOSMolecular Weight: 326.34Target: OthersPathway: OthersStorage: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-2
18、0C 1 monthSolvent Need ultrasonic and warming)ConcentrationSolvent Mass 1 mg 5 mg 10 mg1 mM 3.0643 mL 15.3214 mL 30.6429 mL5 mM 0.6129 mL 3.0643 mL 6.1286 mLPreparing Stock Solutions10 mM 0.3064 mL 1.5321 mL 3.0643 mLPlease refer to the solubility information to select the appropriate solvent.BIOLOG
19、ICAL ACTIVITYDimesna is an protective agent used to decrease urotoxicity.IC50 value:Target:in vitro: Dimesna modulates paclitaxel-induced hyperpolymerization of MTP in a dose-dependent manner, and mesna, an in vivo metabolite of Dimesna, protects against time-dependent cisplatin-induced inactivation
20、 of MTP. 1 Dimesna -mediated prevention or mitigation of cisplatin-induced nephrotoxicity may involve aminopeptidase N (APN) inhibition by certain Dimesna -derived esna-disulfide heteroconjugates and appears correlated to the presence of a glycinate moiety and/or an anionic group. Two general mechan
21、isms for Dimesna -mediated nephroprotection of cisplatin-induced nephrotoxicity involving the gamma-glutamyl transpeptidase (GGT), APN and cysteine-conjugated-lyase (CCBL) nephrotoxigenic pathway are proposed which acting in a concerted and/or synergistic manner, and thereby prevent or mitigate cisplatin-induced renal toxicity. 2 Mesna and its dimer, Dimesna, are coadministered for mitigation of ifosfamide- and cisplatin-induced toxicities, respectively. Dimesna is sel
